Schnieders Capital Management buys $3,150,527 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Schnieders Capital Management scooped up 2,735 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 69,934 shares of Abbott Laboratories which is valued at $3,150,527.Abbott Laboratories makes up approximately 1.73% of Schnieders Capital Management’s portfolio.

Other Hedge Funds, Including , Cadinha Co reduced its stake in ABT by selling 176 shares or 0.82% in the most recent quarter. The Hedge Fund company now holds 21,410 shares of ABT which is valued at $964,521. Abbott Laboratories makes up approx 0.20% of Cadinha Co’s portfolio.Ifc Holdings Incorporatedfl reduced its stake in ABT by selling 158 shares or 1.12% in the most recent quarter. The Hedge Fund company now holds 13,931 shares of ABT which is valued at $626,198. Abbott Laboratories makes up approx 0.07% of Ifc Holdings Incorporatedfl’s portfolio.Northside Capital Management boosted its stake in ABT in the latest quarter, The investment management firm added 346 additional shares and now holds a total of 9,503 shares of Abbott Laboratories which is valued at $414,996. Abbott Laboratories makes up approx 0.19% of Northside Capital Management’s portfolio. First National Bank Of Mount Dora Trust Investment Services sold out all of its stake in ABT during the most recent quarter. The investment firm sold 4,797 shares of ABT which is valued $204,592.Gateway Investment Advisers boosted its stake in ABT in the latest quarter, The investment management firm added 1,008 additional shares and now holds a total of 1,271,318 shares of Abbott Laboratories which is valued at $53,357,216. Abbott Laboratories makes up approx 0.45% of Gateway Investment Advisers’s portfolio.

Abbott Laboratories opened for trading at $45.2 and hit $45.23 on the upside on Monday, eventually ending the session at $45.15, with a gain of 0.24% or 0.11 points. The heightened volatility saw the trading volume jump to 65,25,830 shares. Company has a market cap of $66,370 M.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.